Decheng Capital Management III
Latest statistics and disclosures from Decheng Capital Management III's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALPN, ZNTL, AURA, ROIV, SLRN, and represent 56.72% of Decheng Capital Management III's stock portfolio.
- Added to shares of these 10 stocks: ALPN (+$77M), ROIV (+$17M), AURA (+$14M), LNTH (+$9.9M), ImmunoGen (+$6.6M), Seagen, BYSI, ATRC, PYXS, WGS.
- Started 9 new stock positions in LNTH, ImmunoGen, Seagen, ALPN, PYXS, WGS, ATRC, BYSI, ROIV.
- Reduced shares in these 10 stocks: Alabama Power Co. p (-$69M), Roivant Sciences (-$15M), BeyondSpring (-$5.9M), Seattle Genetics, AtriCure, Apexigen, Sema4 Holdings C, ACET, Neubase Therapeutics Ord, SLRN.
- Sold out of its positions in AtriCure, BeyondSpring, Roivant Sciences, Alabama Power Co. p, Apexigen, Neubase Therapeutics Ord, Seattle Genetics, Sema4 Holdings C.
- Decheng Capital Management III was a net buyer of stock by $38M.
- Decheng Capital Management III has $300M in assets under management (AUM), dropping by -6.01%.
- Central Index Key (CIK): 0001747821
Tip: Access up to 7 years of quarterly data
Positions held by Decheng Capital Management III consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Decheng Capital Management III
Decheng Capital Management III holds 26 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alpine Immune Sciences (ALPN) | 25.6 | $77M | NEW | 6.7M | 11.45 |
|
| Zentalis Pharmaceuticals (ZNTL) | 14.1 | $42M | 2.1M | 20.06 |
|
|
| Aura Biosciences (AURA) | 6.1 | $18M | +296% | 1.2M | 15.69 |
|
| Roivant Sciences Ltd Shs Isin #bmg762791017 (ROIV) | 5.7 | $17M | NEW | 1.5M | 11.68 |
|
| Acelyrin (SLRN) | 5.3 | $16M | 1.5M | 10.17 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 5.2 | $16M | 870k | 17.95 |
|
|
| 10x Genomics Cl A Com (TXG) | 4.9 | $15M | 360k | 41.25 |
|
|
| Argenx SE SHS (ARGX) | 4.5 | $14M | 27k | 491.63 |
|
|
| Pacific Biosciences of California (PACB) | 4.1 | $12M | 1.5M | 8.35 |
|
|
| Illumina (ILMN) | 3.7 | $11M | 81k | 137.28 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 3.3 | $9.9M | NEW | 142k | 69.48 |
|
| Horizon Therapeutics | 3.0 | $9.1M | 79k | 115.69 |
|
|
| Phathom Pharmaceuticals (PHAT) | 2.9 | $8.8M | 850k | 10.37 |
|
|
| ImmunoGen | 2.2 | $6.6M | NEW | 416k | 15.87 |
|
| Seagen | 1.6 | $4.9M | NEW | 23k | 212.15 |
|
| Cue Health (HLTH) | 1.3 | $4.0M | 9.0M | 0.44 |
|
|
| BeyondSpring SHS (BYSI) | 1.3 | $4.0M | NEW | 5.0M | 0.80 |
|
| Terns Pharmaceuticals (TERN) | 1.2 | $3.6M | 714k | 5.03 |
|
|
| Equillium (EQ) | 1.1 | $3.3M | 4.4M | 0.74 |
|
|
| Aadi Bioscience (AADI) | 0.9 | $2.5M | 526k | 4.84 |
|
|
| AtriCure (ATRC) | 0.7 | $2.0M | NEW | 46k | 43.80 |
|
| Scynexis Com New (SCYX) | 0.4 | $1.3M | 556k | 2.28 |
|
|
| Mersana Therapeutics (MRSN) | 0.4 | $1.1M | 904k | 1.27 |
|
|
| Pyxis Oncology (PYXS) | 0.2 | $650k | NEW | 327k | 1.99 |
|
| GeneDx Holdings Corp. Com Cl A (WGS) | 0.1 | $377k | NEW | 104k | 3.64 |
|
| Adicet Bio (ACET) | 0.1 | $274k | -60% | 200k | 1.37 |
|
Past Filings by Decheng Capital Management III
SEC 13F filings are viewable for Decheng Capital Management III going back to 2022
- Decheng Capital Management III 2023 Q3 restated filed Dec. 12, 2023
- Decheng Capital Management III 2023 Q3 restated filed Nov. 29, 2023
- Decheng Capital Management III 2023 Q3 filed Nov. 13, 2023
- Decheng Capital Management III 2023 Q2 filed July 28, 2023
- Decheng Capital Management III 2023 Q1 filed May 10, 2023
- Decheng Capital Management III 2022 Q4 filed Feb. 9, 2023
- Decheng Capital Management III 2022 Q3 filed Nov. 8, 2022
- Decheng Capital Management III 2022 Q2 filed Aug. 1, 2022
- Decheng Capital Management III 2022 Q1 filed May 10, 2022